Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ACAD Stock Forecast 2025-2026
$14.73
Current Price
$2.47B
Market Cap
Buy 12
Hold 7
Sell 1
Wall St Analyst Ratings
Distance to ACAD Price Targets
+151.2%
To High Target of $37.00
+69.7%
To Median Target of $25.00
-25.3%
To Low Target of $11.00
ACAD Price Momentum
+2.4%
1 Week Change
-13.7%
1 Month Change
-11.8%
1 Year Change
-19.7%
Year-to-Date Change
-28.8%
From 52W High of $20.68
+9.9%
From 52W Low of $13.40
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching ACADIA (ACAD) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ACAD and similar high-potential opportunities.
Latest ACAD Stock Price Targets & Analyst Predictions
Based on our analysis of 31 Wall Street analysts, ACAD has a bullish consensus with a median price target of $25.00 (ranging from $11.00 to $37.00). The overall analyst rating is Buy (7.7/10). Currently trading at $14.73, the median forecast implies a 69.7% upside. This outlook is supported by 12 Buy, 7 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Charles Duncan at Cantor Fitzgerald, projecting a 151.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ACAD Analyst Ratings
12
Buy
7
Hold
1
Sell
ACAD Price Target Range
Low
$11.00
Average
$25.00
High
$37.00
Current: $14.73
Latest ACAD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ACAD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 8, 2025 | Needham | Ami Fadia | Buy | Reiterates | $28.00 |
| Mar 7, 2025 | Morgan Stanley | Jeffrey Hung | Equal-Weight | Assumes | $20.00 |
| Feb 27, 2025 | Needham | Ami Fadia | Buy | Reiterates | $28.00 |
| Feb 27, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $27.00 |
| Feb 27, 2025 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $28.00 |
| Feb 11, 2025 | Deutsche Bank | Neena Bitritto-Garg | Hold | Initiates | $22.00 |
| Jan 3, 2025 | Guggenheim | Yatin Suneja | Neutral | Downgrade | $20.00 |
| Nov 7, 2024 | Needham | Ami Fadia | Buy | Reiterates | $28.00 |
| Nov 7, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $27.00 |
| Oct 10, 2024 | Raymond James | Danielle Brill | Market Perform | Reinstates | $0.00 |
| Aug 8, 2024 | UBS | Ashwani Verma | Buy | Maintains | $23.00 |
| Aug 8, 2024 | Citigroup | David Hoang | Buy | Maintains | $23.00 |
| Aug 8, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $27.00 |
| Aug 7, 2024 | RBC Capital | Gregory Renza | Outperform | Maintains | $26.00 |
| Aug 7, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Maintains | $28.00 |
| Aug 7, 2024 | Morgan Stanley | Jeffrey Hung | Equal-Weight | Downgrade | $20.00 |
| Aug 7, 2024 | Needham | Ami Fadia | Buy | Maintains | $28.00 |
| Jul 12, 2024 | Morgan Stanley | Jeffrey Hung | Overweight | Maintains | $28.00 |
| Jun 27, 2024 | BMO Capital | Keith Tapper | Outperform | Initiates | $31.00 |
| Jun 25, 2024 | RBC Capital | Gregory Renza | Outperform | Reiterates | $29.00 |
Acadia Pharmaceuticals Inc. (ACAD) Competitors
The following stocks are similar to ACADIA based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Acadia Pharmaceuticals Inc. (ACAD) Financial Data
Acadia Pharmaceuticals Inc. has a market capitalization of $2.47B with a P/E ratio of 10.8x. The company generates $957.80M in trailing twelve-month revenue with a 23.6% profit margin.
Revenue growth is +12.4% quarter-over-quarter, while maintaining an operating margin of +2.7% and return on equity of +38.9%.
Valuation Metrics
Market Cap
$2.47B
Enterprise Value
$1.75B
P/E Ratio
10.8x
PEG Ratio
18.0x
Price/Sales
2.6x
Growth & Margins
Revenue Growth (YoY)
+12.4%
Gross Margin
+91.6%
Operating Margin
+2.7%
Net Margin
+23.6%
EPS Growth
+213.9%
Financial Health
Cash/Price Ratio
+30.8%
Current Ratio
2.4x
Debt/Equity
7.1x
ROE
+38.9%
ROA
+5.4%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Acadia Pharmaceuticals Inc. (ACAD) Business Model
About Acadia Pharmaceuticals Inc.
What They Do
Develops innovative medicines for CNS disorders.
Business Model
Acadia Pharmaceuticals generates revenue by developing and commercializing specialized drugs that address unmet needs in central nervous system disorders. The company focuses on creating effective treatments for conditions like Parkinson's disease psychosis, thereby enhancing patient outcomes while minimizing side effects commonly associated with antipsychotic medications.
Additional Information
Acadia is based in San Diego, California, and actively collaborates with research institutions to further scientific understanding in neurology. The company seeks to expand its drug portfolio through research-driven strategies and partnerships, indicating a commitment to addressing a wide range of CNS disorders.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
653
CEO
Ms. Catherine E. Owen Adams
Country
United States
IPO Year
2004
Website
www.acadia.comAcadia Pharmaceuticals Inc. (ACAD) Latest News & Analysis
Latest News
Quick Summary
Acadia Pharmaceuticals Inc. will report Q1 financial results on May 7, 2025, after market close, followed by a conference call at 4:30 p.m. ET. Webcast available on their website.
Why It Matters
The announcement of Acadia Pharmaceuticals' Q1 financial results and the accompanying conference call provides critical insights into the company's performance, influencing stock valuation and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Acadia Pharmaceuticals granted inducement awards of 172,637 stock options and 64,791 RSUs to 22 new employees on April 3, 2025, under its 2024 Inducement Plan.
Why It Matters
The grant of stock options and RSUs signals Acadia's commitment to attract talent, potentially boosting innovation and performance, impacting future growth and stock value.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Acadia (ACAD) experienced significant trading volume recently, but upcoming earnings estimate revisions may hinder its short-term price momentum.
Why It Matters
Acadia's significant trading volume signals heightened interest, but negative earnings estimate revisions could hinder its short-term price momentum, impacting investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Acadia (ACAD) reported earnings 30 days ago; investors may want to monitor upcoming developments and stock performance following the earnings release.
Why It Matters
Recent earnings reports can signal a company's financial health and future performance, influencing stock price and investor sentiment. Monitoring upcoming developments is crucial for investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Acadia Pharmaceuticals will participate in three virtual investor conferences in March and April 2025. Webcasts will be available for each event.
Why It Matters
Acadia Pharmaceuticals’ participation in upcoming investor conferences signals engagement with the investment community, potentially affecting stock perception and interest in its pipeline developments.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
ACAD's Q4 results showed earnings missed estimates, but revenues exceeded expectations, boosted by year-over-year growth in sales of Nuplazid and Daybue.
Why It Matters
Mixed results indicate potential volatility in ACAD's stock. Earnings miss may raise concerns, while revenue growth suggests strong demand for products, influencing future performance and investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Negative
Frequently Asked Questions About ACAD Stock
What is Acadia Pharmaceuticals Inc.'s (ACAD) stock forecast for 2025?
Based on our analysis of 31 Wall Street analysts, Acadia Pharmaceuticals Inc. (ACAD) has a median price target of $25.00. The highest price target is $37.00 and the lowest is $11.00.
Is ACAD stock a good investment in 2025?
According to current analyst ratings, ACAD has 12 Buy ratings, 7 Hold ratings, and 1 Sell ratings. The stock is currently trading at $14.73. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ACAD stock?
Wall Street analysts predict ACAD stock could reach $25.00 in the next 12 months. This represents a 69.7% increase from the current price of $14.73. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Acadia Pharmaceuticals Inc.'s business model?
Acadia Pharmaceuticals generates revenue by developing and commercializing specialized drugs that address unmet needs in central nervous system disorders. The company focuses on creating effective treatments for conditions like Parkinson's disease psychosis, thereby enhancing patient outcomes while minimizing side effects commonly associated with antipsychotic medications.
What is the highest forecasted price for ACAD Acadia Pharmaceuticals Inc.?
The highest price target for ACAD is $37.00 from Charles Duncan at Cantor Fitzgerald, which represents a 151.2% increase from the current price of $14.73.
What is the lowest forecasted price for ACAD Acadia Pharmaceuticals Inc.?
The lowest price target for ACAD is $11.00 from at , which represents a -25.3% decrease from the current price of $14.73.
What is the overall ACAD consensus from analysts for Acadia Pharmaceuticals Inc.?
The overall analyst consensus for ACAD is bullish. Out of 31 Wall Street analysts, 12 rate it as Buy, 7 as Hold, and 1 as Sell, with a median price target of $25.00.
How accurate are ACAD stock price projections?
Stock price projections, including those for Acadia Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 9:08 AM UTC